Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer

Background MET expression and activation appear to be important for initiation and progression of triple-negative breast cancer. Tivantinib (ARQ 197) is an orally administered agent that targets MET, although recent preclinical data suggests the agent may have mechanisms of action that are independe...

Descripción completa

Detalles Bibliográficos
Autores principales: Tolaney, Sara M., Tan, Sally, Guo, Hao, Barry, William, Van Allen, Eliezer, Wagle, Nikhil, Brock, Jane, Larrabee, Katherine, Paweletz, Cloud, Ivanova, Elena, Janne, Pasi, Overmoyer, Beth, Wright, John J., Shapiro, Geoffrey I., Winer, Eric P., Krop, Ian E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Phase II Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608248/
https://www.ncbi.nlm.nih.gov/pubmed/26123926
http://dx.doi.org/10.1007/s10637-015-0269-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608248/
https://www.ncbi.nlm.nih.gov/pubmed/26123926
http://dx.doi.org/10.1007/s10637-015-0269-8

Ejemplares similares